Regenics shareholders as of April 2021.

Latest:

- March 31st 2021: Exercise of  122.305 Subscription Rights at 17.15 NOK/share

(minor deviations of % share holdings due to rounding of integers, may apply)  

 

 

SHARES

%

Philippe Collas

189.500

3,0

Runhild Gammelsæter

94.200

1,5

Camilla Haglerød

22.000

0,3

Rune Nilsen

100.000

1,6

Life Capitol AS

1.764.250

28,1

Greyston Holding AS

117.300

1,9

Capra Invest AS

160.800

2,6

ETG Resources AS

38.812

0,6

TVVT Invest AS

78.688

1,3

Heldrup AS

1.831.200

29,1

Marcus Heldrup

100.800

1,6

Cornucopia AS

628.800

10,0

Intento AS

432.800

6,9

Gry Lønne Eriksson

65.000

1,1

 WLH Invest AS

200.584

3,2

 Solvik Holding AS

 81.610

1,3

 Bent Eriksen AS

 31.241

0,8

 Siesta Invest AS

 53.000

0,5

 Høgnipa AS

 299.050

4,8

SUM

6.284.635

100,00

 

Collas AS : Philippe Collas, Founder and Scientific Advisor

Runhild Gammelsæter: former CEO, private

Camilla Haglerød: former CEO, private

Rune Nilsen: private

Life Capitol AS: Jan Remmereit, founder

Greystone Holding AS: Jan Remmereit, founder

Heldrup AS: Tore Heldrup Rasmussen, Chairman Board

Markus Heldrup: Head of production, CPO, employee

Cornucopia AS: Henrik Lund, CEO, consultant

Intento AS: Christian Clemm, CMO, employee

Gry Lønne Eriksson:  Gry Lønne Eriksson, CSO, employee

WLH Invest AS: private

Solvik Holding AS: private

Bent Eriksen AS: private

Siesta Invest AS: private

ETG Resources AS: private

TVTT Invest AS: private

Høgnipa AS: private

 

Share issues/subscription rigths:

2018: Gross proceeds 2.25 mill NOK

2020: Gross proceeds 0.50 mill NOK

2021: Subscription rights 2.10 mill NOK

Protocols (password required):

 

Annual Meeting 2018

Ex. Ord. Annual Meeting 2018

Annual Meeting 2019

Ex. Ord. Annual Meeting 2019

Annual Meeting 2020

Ex. Ord. Annual Meeting 2020

AGM 2020 protocol

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.